secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001006837-25-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INNOVATE reports Q4 revenue down 34.5% to $236.6M; net loss widens to $16.9M; MediBeacon TGFR receives FDA approval
--------------------------------------------------------------------------------

- Q4 2024 revenue $236.6M (-34.5% YoY); net loss attributable to common $16.9M ($1.29 loss per share).
- Full year 2024 revenue $1.11B (-22.2% YoY); Adjusted EBITDA $71.3M (+9.7% YoY).
- Infrastructure segment Q4 revenue $225.7M (-36.2%); adjusted backlog $1.1B; added >$500M to backlog post-year-end.
- MediBeacon TGFR received FDA approval Jan 2025 for kidney function assessment; also NMPA approval in China Feb 2025.
- Broadcasting Q4 revenue $6.8M (+19.3% YoY); Life Sciences revenue $4.1M (R2 unit sales +113% Q4 YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000020/0001006837-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000020/hchc-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001006837-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer